title: Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature.
abstract: BACKGROUND
  Bexarotene was approved for cutaneous T-cell lymphoma (CTCL) in 1999. Apart from the two first clinical trials published ten years ago, very few data were published on the long-term use of bexarotene in CTCL patients.
  
  
  OBJECTIVE
  We performed a retrospective review of CTCL patients treated with bexarotene at a single skin Cancer department between 2002 and 2012. We aimed to determine retrospectively the long-term tolerability and outcome of bexarotene in a cohort of CTCL patients and to compare these results with data from the literature.
  
  
  RESULTS
  Thirty-two patients were included (18 men/14 women); 20 patients had a mycosis fungoïdes and 12 a Sézary syndrome. The longest bexarotene treatment duration observed was 65.2 months and 10 patients were treated for more than 24 months. A clinical response was reported in 60% of all patients and in 75% of patients with Sézary syndrome. Most common drug-related adverse events were hypothyroidism (94%), hypertriglyceridemia (78%) and hypercholesterolemia (44%). Most events (84%) were mild to moderate.
  
  
  CONCLUSIONS
  This study with a very long observation time confirms that bexarotene is well tolerated by CTCL patients during long-term use. It is effective in early and advanced stages of CTCL.
authors.affiliation: Nantes University Hospital, Skin Cancer Unit, INSERM 892, 1 Place Alexis Ricordeau 44093, Nantes Cedex, France.
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Quéreux
authors.forename: Melanie
authors.initials: M
authors.lastname: Saint-Jean
authors.forename: Lucie
authors.initials: L
authors.lastname: Peuvrel
authors.forename: Anabelle
authors.initials: A
authors.lastname: Brocard
authors.forename: Anne-Chantal
authors.initials: AC
authors.lastname: Knol
authors.forename: Brigitte
authors.initials: B
authors.lastname: Dréno
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077610:Bexarotene; D005260:Female; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene